These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 26599153)

  • 21. Effective induction of type 1 cytotoxic T cell responses in mice with DNA vaccine encoding two hepatitis C virus cytotoxic T lymphocyte epitopes.
    Shi L; Liu S; Fan GX; Sheng L; Ren HX; Yuan YK
    Viral Immunol; 2006; 19(4):702-11. PubMed ID: 17201665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.
    Sugauchi F; Wang RY; Qiu Q; Jin B; Alter HJ; Shih JW
    J Infect Dis; 2006 Feb; 193(4):563-72. PubMed ID: 16425136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospects for hepatitis C vaccine.
    Bhopale GM; Nanda RK
    Acta Virol; 2004; 48(4):215-21. PubMed ID: 15745044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation between viral fitness and immune escape within the hepatitis C virus protease.
    Söderholm J; Ahlén G; Kaul A; Frelin L; Alheim M; Barnfield C; Liljeström P; Weiland O; Milich DR; Bartenschlager R; Sällberg M
    Gut; 2006 Feb; 55(2):266-74. PubMed ID: 16105887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.
    Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G
    Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial.
    Alvarez-Lajonchere L; Shoukry NH; Grá B; Amador-Cañizares Y; Helle F; Bédard N; Guerra I; Drouin C; Dubuisson J; González-Horta EE; Martínez G; Marante J; Cinza Z; Castellanos M; Dueñas-Carrera S
    J Viral Hepat; 2009 Mar; 16(3):156-67. PubMed ID: 19017255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.
    Houghton M
    Immunol Rev; 2011 Jan; 239(1):99-108. PubMed ID: 21198667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins.
    Pancholi P; Liu Q; Tricoche N; Zhang P; Perkus ME; Prince AM
    J Infect Dis; 2000 Jul; 182(1):18-27. PubMed ID: 10882577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.
    Grollo L; Torresi J; Drummer H; Zeng W; Williamson N; Jackson DC
    Antivir Ther; 2006; 11(8):1005-14. PubMed ID: 17302370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The hypervariable region 1 protein of hepatitis C virus broadly reactive with sera of patients with chronic hepatitis C has a similar amino acid sequence with the consensus sequence.
    Watanabe K; Yoshioka K; Ito H; Ishigami M; Takagi K; Utsunomiya S; Kobayashi M; Kishimoto H; Yano M; Kakumu S
    Virology; 1999 Nov; 264(1):153-8. PubMed ID: 10544140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities.
    Roohvand F; Kossari N
    Expert Opin Ther Pat; 2012 Apr; 22(4):391-415. PubMed ID: 22455502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
    Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
    Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
    Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
    Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective epitope identification employing phylogenetic, mutational variability, sequence entropy, and correlated mutation analysis targeting NS5B protein of hepatitis C virus: from bioinformatics to therapeutics.
    Meshram RJ; Gacche RN
    J Mol Recognit; 2015 Aug; 28(8):492-505. PubMed ID: 25727409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus proteins as targets for drug development: the role of bioinformatics and modelling.
    Lahm A; Yagnik A; Tramontano A; Koch U
    Curr Drug Targets; 2002 Aug; 3(4):281-96. PubMed ID: 12102600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The euHCVdb suite of in silico tools for investigating the structural impact of mutations in hepatitis C virus proteins.
    Combet C; Bettler E; Terreux R; Garnier N; Deléage G
    Infect Disord Drug Targets; 2009 Jun; 9(3):272-8. PubMed ID: 19519481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine.
    Lothert K; Offersgaard AF; Pihl AF; Mathiesen CK; Jensen TB; Alzua GP; Fahnøe U; Bukh J; Gottwein JM; Wolff MW
    Sci Rep; 2020 Oct; 10(1):16261. PubMed ID: 33004836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The hepatitis C sequence database in Los Alamos.
    Kuiken C; Hraber P; Thurmond J; Yusim K
    Nucleic Acids Res; 2008 Jan; 36(Database issue):D512-6. PubMed ID: 18025038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability of the hepatitis C virus genome.
    Simmonds P
    Curr Stud Hematol Blood Transfus; 1998; (62):38-63. PubMed ID: 9507803
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.